Dark

Check out our Level2View

PYXS
Pyxis Oncology, Inc. Common Stock
stock NASDAQ

At Close

Jul 27, 2026 3:59:54 PM EDT

2.91USD+11.494%(+0.30)985,099

2.51Bid 3.33Ask 0.82Spread

Pre-market

Jul 27, 2026 8:10:30 AM EDT

2.63USD+0.766%(+0.02)140

After-hours

Jul 27, 2026 4:33:30 PM EDT

2.91USD0.000%(0.00)8,401

OverviewOptionsHistoricalExchangesShortsNews

Dec 15, 2021

08:19AM EST Pyxis To Be Added To Russell 2000 Index As Of Dec. 20, 2021 Benzinga

08:00AM EST Pyxis to be Added to Russell 2000 Index GlobeNewswire Inc

Dec 9, 2021

08:30AM EST Pyxis Oncology, Inc. (Nasdaq: PYXS) today announced the appointment of Martina Molsbergen as Interim Chief Business Officer. Ms. Molsbergen will be responsible for managing the Companys current partnerships and joint ventures as well as exploring new business development opportunities. GlobeNewswire Inc

Nov 15, 2021

10:57AM EST Pyxis Oncology Q3 EPS $(8.96) Down From $(2.93) YoY Benzinga

07:15AM EST Pyxis Oncology, Inc. (Nasdaq: PYXS), a preclinical oncology company focused on developing next-generation therapeutics for difficult to treat cancers, today reported financial results for its third quarter ended September 30, 2021 and provided a business update. GlobeNewswire Inc

Nov 10, 2021

08:00AM EST Pyxis Oncology to Present at the Jefferies London Healthcare GlobeNewswire Inc

Nov 2, 2021

11:11AM EDT Benzinga's Top Ratings Upgrades, Downgrades For November 2, 2021 Benzinga

10:47AM EDT B of A Securities Initiates Coverage On Pyxis Oncology with Neutral Rating, Announces Price Target of $16 Benzinga

10:42AM EDT Jefferies Initiates Coverage On Pyxis Oncology with Buy Rating, Announces Price Target of $25 Benzinga

10:42AM EDT Credit Suisse Initiates Coverage On Pyxis Oncology with Outperform Rating, Announces Price Target of $19 Benzinga

Oct 31, 2021

02:24PM EDT The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline Benzinga

Oct 12, 2021

08:13AM EDT The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology Benzinga

Oct 8, 2021

11:02AM EDT Pyxis Oncology Shares Open For Trade At $19; IPO Priced At $16/Share Benzinga

10:39AM EDT Pyxis Oncology Indicating $31.20; IPO Priced At $16/Share Benzinga

09:26AM EDT Pyxis Oncology Shares Will Open For Quote At 10:35 a.m. EDT, Expected To Open For Trade After 10:45 a.m. EDT; IPO Priced At $16/Share Benzinga

Oct 7, 2021

11:17PM EDT Pyxis Oncology Prices Upsized IPO Of 10.50 Mln Shares At $16.00/shr RTTNews

10:25PM EDT Pyxis Announces Pricing of Upsized Initial Public Offering GlobeNewswire Inc

Share